Clinical conditions or interventions that disrupt the microbiota—such as broad-spectrum antibiotic therapy, gastrointestinal disease, or major dietary changes—have been associated with altered pharmacokinetics of CYP3A4 substrates [258,259]. Here, CYP3A4 is linked to gastrointestinal disease.